company background image
TNGX

Tango Therapeutics NasdaqGM:TNGX Stock Report

Last Price

US$4.97

Market Cap

US$437.3m

7D

20.6%

1Y

-50.2%

Updated

10 Aug, 2022

Data

Company Financials +
TNGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TNGX Stock Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.

Tango Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tango Therapeutics
Historical stock prices
Current Share PriceUS$4.97
52 Week HighUS$18.84
52 Week LowUS$3.71
Beta0
1 Month Change6.20%
3 Month Change0%
1 Year Change-50.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.42%

Recent News & Updates

Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

TNGXUS BiotechsUS Market
7D20.6%4.3%1.2%
1Y-50.2%-22.1%-11.6%

Return vs Industry: TNGX underperformed the US Biotechs industry which returned -25.9% over the past year.

Return vs Market: TNGX underperformed the US Market which returned -13.5% over the past year.

Price Volatility

Is TNGX's price volatile compared to industry and market?
TNGX volatility
TNGX Average Weekly Movement13.9%
Biotechs Industry Average Movement12.6%
Market Average Movement7.9%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.2%

Stable Share Price: TNGX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: TNGX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201798Barbara Weberhttps://www.tangotx.com

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.

Tango Therapeutics, Inc. Fundamentals Summary

How do Tango Therapeutics's earnings and revenue compare to its market cap?
TNGX fundamental statistics
Market CapUS$437.35m
Earnings (TTM)-US$71.34m
Revenue (TTM)US$36.41m

12.0x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TNGX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$0
EarningsUS$0

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin-138.83%
Net Profit Margin-195.91%
Debt/Equity Ratio0%

How did TNGX perform over the long term?

See historical performance and comparison